Atlas Trials

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Clinical trial NCT02759835 · COMPLETED

Trial details

NCT number
NCT02759835
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lung AdenocarcinomaLung Neoplasms
Start date
2016-04-13
Primary completion
2022-05-25
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.